Table 4.
Performance of PAULA’s test in the combined set (training plus validation) using ROC AUC analysis of 4-biomarker MoM aggregate scores
| Number of cases | Cutoff | AUC | P value | % sensitivity at 83% specificity | |
|---|---|---|---|---|---|
| Early stages (I & II) | 160 | 6.4 | 0.82 | < 0.0001 | 71.2 |
| Late stages (III & IV) | 30 | 6.4 | 0.87 | < 0.0001 | 76.7 |
| Total | 190 | ||||
| Adenocarcinoma | 73 | 6.4 | 0.82 | < 0.0001 | 69.0 |
| Squamous cell carcinoma | 60 | 6.4 | 0.80 | < 0.0001 | 70.0 |
| Bronchioalveolar carcinoma | 28 | 6.4 | 0.89 | < 0.0001 | 85.7 |
| Large cell (incl. LCNEC) | 20 | 6.4 | 0.84 | < 0.0001 | 75.0 |
| Carcinoma, NOS | 5 | 6.4 | 0.85 | 0.0069 | 60.0 |
| Other | 4 | ||||
| Total | 190 | ||||